Carvykti^® (ciltacabtagene autoleucel): Clinical Profile & Patient Journey Guide for Multiple Myeloma

Carvykti is the second BCMA‑targeted CAR‑T therapy approved (after Abecma) and the first to demonstrate superior outcomes compared to standard of care in a Phase 3 trial (CARTITUDE‑4). It is specifically designed for multiple myeloma, a plasma cell malignancy where BCMA is highly expressed.

Carvykti is an autologous BCMA‑directed CAR‑T cell therapy with a distinct CAR structure:

1. T‑Cell Collection: Patient's own T‑cells are collected via leukapheresis.
2. Genetic Modification: T‑cells are transduced with a lentiviral vector encoding a CAR that recognizes BCMA.
3. CAR Structure:
   • Targeting domain: Humanized single‑chain variable fragment (scFv) targeting BCMA
   • Hinge region: CD8α (provides flexibility and stability)
   • Costimulatory domain: 4‑1BB (same as Kymriah, Breyanzi), which promotes T‑cell persistence and reduces exhaustion
   • Signaling domain: CD3ζ, which activates T‑cell cytotoxic function
4. Unique Engineering:
   • High‑affinity BCMA binding optimized for potent cytotoxicity
   • Engineered epitope to reduce immunogenicity (lower risk of anti‑drug antibodies)
5. Expansion: Modified cells are expanded ex vivo to achieve therapeutic doses.
6. Reinfusion: Patient receives lymphodepleting chemotherapy (fludarabine/cyclophosphamide), followed by single infusion of CAR‑T cells.
7. Mechanism: CAR‑T cells bind BCMA on plasma cells (normal and malignant), activate cytotoxic response, and persist long‑term due to 4‑1BB signaling.

Relapsed/Refractory Multiple Myeloma (r/r MM) — Initial Approval February 2022

• Adult patients with relapsed or refractory multiple myeloma who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 antibody
• FDA label: "Adult patients with relapsed or refractory multiple myeloma (MM) who have received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 antibody"

r/r MM — Expanded Approval April 2024

• Adult patients with relapsed or refractory multiple myeloma who have received ≥1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and have demonstrated disease progression on or after lenalidomide
• FDA approval date: April 2024 (significant expansion to earlier line of therapy)
• EMA indication: Similar expansion in 2024

CARTITUDE‑1 Trial (Phase 1b/2, ≥4 Prior Lines)

• Multicenter, open‑label study
• Adult patients with r/r MM after ≥4 prior lines (including PI, IMiD, anti‑CD38)
• Demonstrated high overall response rate (ORR) with durable complete responses
• Long‑term follow‑up (median >24 months) shows sustained responses in responders
• Led to FDA approval in February 2022

CARTITUDE‑2 Trial (Phase 1b/2, ≥1 Prior Line)

• Multicenter, open‑label study
• Adult patients with r/r MM after ≥1 prior line
• Demonstrated high ORR with durable responses
• Supported expanded indication to earlier line of therapy

CARTITUDE‑4 Trial (Phase 3, ≥1 Prior Line) — Landmark

• Randomized, open‑label, Phase 3 trial (highest level of evidence)
• Compared Carvykti vs standard of care (pomalidomide + bortezomib + dexamethasone OR daratumumab + pomalidomide + dexamethasone) in patients with r/r MM after ≥1 prior line
• Demonstrated superior progression‑free survival (PFS) vs standard of care
• Led to FDA expanded approval in April 2024

Carvykti carries significant safety risks that require careful patient selection and monitoring. The following are based on FDA prescribing information and clinical trial data:

Other Serious Adverse Reactions

• Prolonged cytopenias: Neutropenia, thrombocytopenia, anemia (may persist for weeks to months)
• Infections: Increased risk due to B‑cell aplasia and hypogammaglobulinemia; prophylactic antimicrobials and immunoglobulin replacement may be required
• Hemophagocytic lymphohistiocytosis (HLH) / Macrophage activation syndrome (MAS): Rare but potentially fatal
• Hypogammaglobulinemia: Expected on‑target effect due to BCMA expression on normal plasma cells; requires monitoring and immunoglobulin replacement

Long‑Term Monitoring

• Patients must be monitored long‑term for persistent cytopenias, infections, and secondary malignancies
• Annual follow‑up recommended for at least 15 years per FDA requirement
• Close neurologic monitoring for at least 4 weeks post‑infusion due to delayed ICANS risk

(Regulatory status may change. Always verify current approval status with regional regulatory authorities.)

Pricing (Approximate, Out‑of‑Pocket for International Patients)

Total Treatment Cost Considerations

• The drug acquisition cost is only one component.
• Additional costs include:
  • Leukapheresis and cell collection
  • Lymphodepleting chemotherapy
  • Hospitalization (typically 2‑4 weeks minimum)
  • Management of CRS/ICANS (tocilizumab, corticosteroids, ICU care if needed)
  • Extended neurologic monitoring (due to delayed ICANS risk)
  • Long‑term follow‑up and monitoring
  • Immunoglobulin replacement therapy
• Total treatment episode cost can exceed $500,000‑$800,000 in the US when all components are included.

Insurance Coverage & International Access

• Coverage varies significantly by insurer, country, and specific indication.
• Carvykti is available only at certified treatment centers (REMS‑certified in the US or equivalent).
• Our platform can facilitate introductions to certified treatment centers, but we cannot guarantee access or coverage.

Week 0: Decision & Preparation

• Consultation with oncologist · Discussion of risks, benefits, and alternatives · Selection of certified treatment center · Insurance pre‑authorization begins

Week 1‑2: Medical Records Transfer

• Collection of complete medical history, pathology reports, imaging · Secure transfer to treatment center · Initial remote consultation

Week 3‑4: Pre‑Treatment Evaluation

• In‑person consultation · Comprehensive evaluation: cardiac, pulmonary, hepatic, renal function · Education on CRS/ICANS (including delayed ICANS risk)

Week 5‑6: Leukapheresis (T‑Cell Collection)

• 4‑6 hour procedure to collect T‑cells · Cells shipped to manufacturing facility

Week 7‑10: Manufacturing (Waiting Period)

• T‑cells are genetically modified, expanded, and quality‑tested · Typical manufacturing time: 3‑4 weeks · Bridging therapy if needed

Week 11: Hospital Admission & Lymphodepletion

• Admission · 3 days of lymphodepleting chemotherapy (fludarabine + cyclophosphamide) · 1‑2 day rest period

Week 12: CAR‑T Infusion

• Single intravenous infusion (typically 30‑60 minutes) · Close monitoring · Day 0 of post‑infusion monitoring

Week 13‑16: Intensive Monitoring (CRS/ICANS)

• Daily vital signs, neurologic assessments · Monitoring for CRS · Extended neurologic monitoring for delayed ICANS (movement disorders, cognitive changes, seizures) · Treatment with tocilizumab and/or corticosteroids if needed

Week 17‑20: Discharge & Early Recovery

• Discharge if stable · Frequent outpatient follow‑up (2‑3 times per week) · Gradual return to normal activities

Month 2‑3: Continued Monitoring

• Weekly to biweekly outpatient visits · Blood tests · Imaging at day 30 and day 90 · Continued neurologic monitoring

Month 4‑12: Long‑Term Follow‑Up

• Monthly visits, then every 2‑3 months · Annual follow‑up required for at least 15 years

What to Expect Emotionally

• Before treatment: Anxiety, hope, uncertainty are all normal
• During manufacturing: The waiting period (3‑4 weeks) can be especially stressful
• During CRS/ICANS: You may see confusion, personality changes, movement disorders, or physical symptoms — these are usually temporary but require immediate medical attention
• After treatment: Adjustment period as patient recovers strength

Your Role in the Hospital

• You CAN: Provide emotional support, help with communication, assist with daily activities, advocate for patient needs
• You CANNOT: Make medical decisions, stay in the room 24/7, replace the medical team's expertise

Preventing Caregiver Burnout

• Recognize the signs: Exhaustion, irritability, feeling overwhelmed
• Ask for help: Family, friends, hospital social workers, support groups
• Take breaks — you cannot pour from an empty cup

Questions You Should Ask

• What are the signs of CRS/ICANS I should watch for?
• What are the signs of delayed ICANS (movement disorders, cognitive changes)?
• Who do I call if there's an emergency after hours?
• What medications does the patient need to take at home?
• When can the patient return to normal activities?

"Can I have children after Carvykti?"

• The lymphodepleting chemotherapy and CAR‑T therapy may affect fertility. Discuss fertility preservation BEFORE treatment. Pregnancy after CAR‑T is possible but requires careful planning.

"Can I go back to work?"

• Most patients need 2‑3 months off work minimum. Return depends on recovery, blood counts, cognitive function, and energy levels.

"What if the treatment doesn't work?"

• Options may include other BCMA‑targeted therapies (Abecma), bispecific antibodies (Teclistamab, Elranatamab), clinical trials, stem cell transplant, or palliative care.

"Does CAR‑T hurt?"

• Leukapheresis is well‑tolerated. The infusion is usually painless. Chemotherapy and CRS can cause side effects, but these are managed with medications.

"How long will I be away from home?"

• If local: 4‑6 weeks minimum. If traveling internationally: plan for 2‑3 months away from home.

"Can I get vaccinated after CAR‑T?"

• Live vaccines are avoided for at least 6 weeks before and 6 months after CAR‑T. Inactivated vaccines may be given after immune recovery.

Why Might Carvykti Not Work?

• Antigen escape: Cancer cells may lose BCMA expression
• Insufficient CAR‑T expansion: Not enough CAR‑T cells persist
• Disease too advanced: Very high tumor burden may overwhelm the response
• Patient factors: Poor performance status, organ dysfunction

What Are the Next Options?

• Other BCMA‑targeted therapies: Abecma (idecabtagene vicleucel)
• Bispecific antibodies: Teclistamab (BCMA/CD3), Elranatamab (BCMA/CD3)
• Clinical trials with new constructs or other novel therapies
• Allogeneic stem cell transplant
• Palliative care focusing on quality of life

Wait times can be longer if manufacturing delays occur. International patients must factor in travel, accommodation, and extended stay costs. Not all patients are eligible.

These are general pharmacological differences. Individual patient responses vary. Treatment selection should be based on specific clinical circumstances, disease characteristics, and physician recommendation.